Overview:
Chronic myeloid leukemia (CML) remains a complex hematologic malignancy despite dramatic improvements in outcomes with tyrosine kinase inhibitors (TKIs). As six TKIs are now FDA-approved for CML, each with unique efficacy and safety profiles, clinicians face challenges in sequencing these agents, managing resistance, and addressing treatment-related adverse events. Continuous education is needed to help clinicians integrate new evidence, optimize therapeutic decisions, and enhance multidisciplinary collaboration to improve patient outcomes.
To address these gaps, PER will deliver a CME-certified Live,
Webcast, Medical Crossfire® symposium featuring concise didactic updates and
expert panel debate. Through real-world case discussions, polling, and Q&A,
participants will explore the evolving role of TKIs, resistance mechanisms, and
emerging therapies.
Learning Objectives:
Upon completion of this activity, learners will be better able to:
- Analyze the latest clinical data on first-line therapies and apply emerging evidence to optimize initial treatment selection in CML
- Evaluate strategies for treatment sequencing across multiple lines of therapy in CML
- Implement effective approaches to manage adverse events and enhance patient safety
- Develop individualized care plans that improve outcomes and support long-term disease management
Jorge E. Cortes, MD
Director, Georgia Cancer Center
Cecil F. Whitaker Jr, GRA Eminent Scholar Chair in Cancer
Georgia Research Alliance
Augusta University
Augusta, GA
Hagop Kantarjian, MD
Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Neil Shah, MD, PhD
Edward S. Ageno Distinguished Professorship in Hematology/Oncology, UCSF
Professor, Department of Medicine
UCSF
San Francisco, CA
Kendra Sweet, MD
Oncologist
Moffitt Cancer Center
Tampa, FL
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.5 Contact Hours.